Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma

Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma Letters used in Gerami et al, which was selected to understand the Mohs Appropriate Use Criteria true NPV (above 99%) in the clinical setting and not simply for Superficial Basal Cell Carcinoma in a research validation setting. Again, by way of comparison To the Editor We read with interest the Viewpoint by Steinman with the current histopathologic pathway using a 7% preva- and colleagues suggesting a reevaluation of appropriate use lence, the calculated NPV from Elmore et al for early-stage criteria for Mohs micrographic surgery (MMS) with respect to melanoma based on the sensitivity described herein is well primary superficial basal cell carcinoma (sBCC). We must note 1,4,5 below 83%. It is also important to note that 708 PLA- that MMS is only 1 means of margin control of skin cancers, evaluated real-world lesions have now been followed up for and perhaps the Viewpoint title would more accurately read over a year, and no missed melanomas have been identified “Reevaluation of Excisional Surgery for Primary Basal Cell (D.M.S. and Laura K. Ferris, MD, PhD, unpublished observa- Carcinoma.” tions), further supporting the high NPV of the PLA. The authors assert that “studies of sBCCs treated with We agree that it http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma

JAMA Dermatology , Volume 155 (3) – Mar 6, 2019

Loading next page...
 
/lp/american-medical-association/mohs-appropriate-use-criteria-for-superficial-basal-cell-carcinoma-jnxeOO10B5
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2018.5661
Publisher site
See Article on Publisher Site

Abstract

Letters used in Gerami et al, which was selected to understand the Mohs Appropriate Use Criteria true NPV (above 99%) in the clinical setting and not simply for Superficial Basal Cell Carcinoma in a research validation setting. Again, by way of comparison To the Editor We read with interest the Viewpoint by Steinman with the current histopathologic pathway using a 7% preva- and colleagues suggesting a reevaluation of appropriate use lence, the calculated NPV from Elmore et al for early-stage criteria for Mohs micrographic surgery (MMS) with respect to melanoma based on the sensitivity described herein is well primary superficial basal cell carcinoma (sBCC). We must note 1,4,5 below 83%. It is also important to note that 708 PLA- that MMS is only 1 means of margin control of skin cancers, evaluated real-world lesions have now been followed up for and perhaps the Viewpoint title would more accurately read over a year, and no missed melanomas have been identified “Reevaluation of Excisional Surgery for Primary Basal Cell (D.M.S. and Laura K. Ferris, MD, PhD, unpublished observa- Carcinoma.” tions), further supporting the high NPV of the PLA. The authors assert that “studies of sBCCs treated with We agree that it

Journal

JAMA DermatologyAmerican Medical Association

Published: Mar 6, 2019

References